Psychedelics and neurostimulation for treatment resistant psychiatric disorders.
Filip Blazek, Klara Latalova, David Krahulik, Lumir Hrabalek
Discover Mental Health May 25, 2026 DOI: 10.1007/s44192-026-00486-5 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key points | Proposes that psychedelic-assisted therapy and neurostimulation share mechanisms of neuroplasticity and network reconfiguration, and outlines strategies for integrating them into circuit-focused mental health care. |
Abstract
Psychedelic-assisted therapy and neurostimulation represent converging approaches to modulating dysfunctional brain circuits in treatment-resistant psychiatric disorders. This Perspective outlines shared mechanisms involving neuroplasticity and network reconfiguration, and examines ethical, regulatory, and infrastructural barriers to their translation. Bridging neuroscience, psychiatry, and policy, it proposes strategies for integrating these innovative interventions into evidence-based, circuit-focused models of mental health care.
Citations in the library
Cites 12
- mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists Science August 19, 2010
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics Pharmacological Reviews June 20, 2019
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
and 7 more in the library